Phoenix Children's Hospital
Phoenix Children's Hospital is one of the 10 largest children's
hospitals in the country and provides specialty and sub-specialty inpatient, outpatient, trauma, and emergency
care to patients throughout Arizona and other Southwestern states.
The Center for Cancer and Blood Disorders at Phoenix Children's Hospital
is the largest pediatric program of its kind in Arizona, providing complete care for children diagnosed with
malignancies and hematologic diseases. In 2013, 289 children newly diagnosed with cancer were treated at Phoenix
Children's. The Center includes multidisciplinary clinical programs in Leukemia/Lymphoma/Histiocytosis, Solid
Tumors, Neuro-oncology, Bone Marrow Transplant, Coagulation Disorders, Hemoglobinopathies, and Survivor/Long Term Follow-up.
The Center's Oncology Research Program supports all phases (I, II, III) of clinical trials with 7 full time research
staff members. It is the only hospital in Arizona as well the Southwestern Tristate area which is conducting pediatric
phase I and II clinical trials in oncology. There are currently over 100 research studies open at the institution. The
program includes a comprehensive Early Drug Development Program with physicians representing each of the clinical specialty
areas as well as a full time research nurse and a full time research coordinator. Phoenix Children's is an active participant
in multiple clinical trial consortia, including the Children's Oncology Group (COG), Pediatric Oncology Experimental Therapeutics
Investigators' Consortium (POETIC), the Neuroblastoma and Medulloblastoma Translation Research Consortium (NMTRC), and the
Pediatric Bone Marrow Transplant Consortium (PBMTC).
Additionally, Phoenix Children's Hospital recently established the Ron Matricaria Institute of Molecular Medicine. The goal
of the Institute is to develop personalized medicine for patients, targeting specific molecular markers in each patient's cancer
cells. This will be closely integrated with the Early Drug Development Program, enabling early clinical trials of this approach
using the most promising molecularly targeted agents available.
by Alexis S., age 3
Acute Lymphocytic Leukemia